Sun Pharmaceutical on Thursday said it has filed application for manufacturing and marketing authorisation of Tildrakizumab, used to treat psoriasis and psoriatic arthritis, with Japanese health authority.
The company's wholly-owned subsidiary has filed the application with Pharmaceuticals and Medical Devices Agency (PMDA), Japan, Sun Pharma said in a statement.
"Sun Pharma is committed to growing its global dermatology franchise, with Tildrakizumab as its lead product. We continue to build our pipeline and capabilities in this important therapeutic area of significant unmet need," Sun Pharma EVP & Head Global Business Development Kirti Ganorkar said.
This filing in Japan is a step forward for Sun Pharma in expanding the global franchise for the product, he added.
The recent acquisition of Pola Pharma (Pola) in Japan will help Sun Pharma leverage Pola's strong presence in the dermatology segment to commercialise Tildrakizumab post regulatory approval.
The Mumbai-based drug major had announced the closure of the Pola acquisition in January 2019.
Disclaimer: No Business Standard Journalist was involved in creation of this content
